

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C., 20231, on:

Date: Nov. 7, 1997

By: C. A. Stratford

DOCKET No.: 5865-0009.31

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF:

G.A. Amstutz, et al.

SERIAL No.: 08/496,847

FILED: June 27, 1995

FOR: METHODS AND FORMULATIONS FOR
PREVENTING PROGRESSION OF
NEUROPATHIC PAIN

EXAMINER: Davenport

ART UNIT: 1811

RECEIVED

NOV 17 1997

GROUP 1800

Response to Notice to Comply with Requirements for
Patent Applications Containing Nucleotide Sequence
and/or Amino Acid Sequence Disclosures

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Notice to Comply With Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures mailed August 7, 1997 (copy attached), applicant herewith transmits a sequence listing, computer-readable copy (floppy disc) thereof and statement confirming matching of printed and computer-readable text, and a Preliminary Amendment to the subject application.

No additional fees are believed due in connection with this response and the enclosed papers. However, should fees be found to be due in respect thereof, the Assistant Commissioner for Patents is hereby authorized to charge such fee or fees to counsel's Deposit Account No. 04-0531. A duplicate copy of this response is provided.

Respectfully submitted,


C. A. Stratford

Carol A. Stratford
Registration No. 34,444

Date: Nov 7, 1997

Correspondence Address:

Dehlinger & Associates, LLP
P.O. Box 60850
Palo Alto, CA 94306
Phone: (650) 324-0880



I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C., 20231, on:

Date: Nov 7, 1997

By: C. A. Stratford

DOCKET No.: 5865-0009.31

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF:

G.A. Amstutz, et al.

SERIAL No.: 08/496,847

FILED: June 27, 1995

FOR: METHODS AND FORMULATIONS FOR
PREVENTING PROGRESSION OF
NEUROPATHIC PAIN

EXAMINER: Davenport

ART UNIT: 1811

RECEIVED

Nov 17 1997

CRD/JP 1800

Declaration Under 37 CFR §1.821

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

I, Carol A. Stratford, declare and affirm as follows:

1. I am an agent for the applicant.
2. The floppy disc which accompanies this Declaration contains the required sequence listing.
3. The sequence listing recorded on said disc matches the hard copy of the sequence listing accompanying this Declaration.
4. The present submission contains no new matter relative to the application as originally filed.

Respectfully submitted,


C. A. Stratford

Carol A. Stratford
Registration No. 34,444

Date: Nov 7, 1997

Correspondence Address:

Dehlinger & Associates, LLP
P.O. Box 60850
Palo Alto, CA 94306
Phone: (650) 324-0880



Application No.: 08/496847

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.

2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).

3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).

4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."

5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).

6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).

7. Other: _____

Applicant Must Provide:

An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".

An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.

A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

For PatentIn software help, call (703) 308-6856

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE